Research being conducted at the National Cancer Institute in America has discovered a new treatment for cancer consisting of genetically engineered CD4 T cells. These cells, which are part of the body’s immune system, target a protein called MAGE-A3 and help other T cells, such as CD8 T cells in the immune response. The researchers suggest that the genetically engineered CD4 T cells could have potential in all metastatic cancers.

In the following article, Yong-Chen William Lu, PhD, is interviewed by Targeted Oncology, and discusses a phase I dose-escalation study investigating the genetically engineered CD4 T cells ability to target the MAGE-A3 protein, as well as the treatment’s potential toxicities and currently ongoing responses in some patients still enrolled in the trial.

Read more here